Ranolazine to treat early cardiotoxicity induced by antitumor drugs

ABSTRACT: Primary objectives: Efficacy: Efficacy of five weeks ranolazine on post-chemotherapy diastolic dysfunction at echocardiography, and/or PDS at SPECT, and/or Nt-proBNP elevation. Safety: Objective and subjective tolerability of five weeks ranolazine in post-chemotherapy cancer patients Primary endpoints: Efficacy: Efficacy will be evaluated as improvement or disappearance of abnormalities detected at the post-chemotherapy assessment. To evaluate the efficacy of 5 weeks ranolazine, the abnormalities detected in a given patient at the post-chemotherapy assessment will be compared to the same abnormalities detected in that patient at the 5 weeks early reassessment. Safety: The tolerability of 5 weeks ranolazine will be evaluated by describing all drug-related adverse events such as constipation, nausea, dizziness or any abnormality at laboratory tests.

DISEASE(S): Patients Who Completed Standard Dose Chemotherapy For The Treatment Of Non-hodgkin Lymphoma Or The Adjuvant Treatment Of Breast Cancer Or Colorectal Cancer.

PROVIDER: 2527372 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR